|Bid||62.50 x 800|
|Ask||66.75 x 1200|
|Day's Range||64.98 - 66.36|
|52 Week Range||53.63 - 71.70|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||122.27|
|Forward Dividend & Yield||1.44 (2.34%)|
|Ex-Dividend Date||Feb 24, 2022|
|1y Target Est||72.40|
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Kevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.
The European health regulator on Thursday endorsed the use of AstraZeneca's COVID vaccine, Vaxzevria, as a booster. The recommendation, made by a committee of the European Medicines Agency (EMA), encompasses adults who have either been previously vaccinated by Vaxzevria or an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna. The recommendation comes weeks after the EMA backed the use of Pfizer-BioNTech's Comirnaty as a booster for adults who have previously been inoculated with other vaccines.